Pozelimab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Pozelimab. Educational only — not medical advice.
Labeled uses
VEOPOZ is indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.
Source: FDA labeling via NIH DailyMed (set a8d6f10e…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.